Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01999738 (Clinical Trial / EC1456)

Study Title
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors NCT01999738

Trial Description
Phase 1, multicenter, open-label, non-randomized, dose-escalation oncology study to evaluate the administration of EC1456, BIW on Weeks 1 and 2 of a 4-week schedule (Part A), and to assess preliminary efficacy results in focused patients with triple-negative breast cancer (TNBC), advanced non-small cell lung cancer (NSCLC), ovarian cancer and hepatocellular carcinoma (HCC) (10 patients each) treated at the MTD (Part B).

This trial is sponsored by Endocyte. [1]

Study Data

  • Condition:
    • Solid Tumors
    • Triple-Negative Breast Cancer
    • Advanced Non-Small Cell Lung Cancer
    • Ovarian Cancer
    • Hepatocellular Carcinoma
  • Interventions:
    • Drugs used in this trial
      • etarfolatide (EC20)
      • EC1456
  • Phase: I
  • Estimated Enrollment: 30
  • Start: October 2013
  • Estimated Completion: July 2016
  • Last verified: August 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: October 1, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar